Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
Brain metastasis
Breast cancer
HER2+
Leptomeningeal
Trastuzumab deruxtecan
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
26
04
2024
accepted:
05
07
2024
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
aheadofprint
Résumé
We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer with brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.6 months. Median overall survival (OS) was not reached (NR); 24-month OS rate was 56.0%. Subgroup analysis showed that median PFS was 13.2 months in patients with analytical active BM, 17.5 months in patients with leptomeningeal carcinomatosis (LMC), and NR in patients with analytical stable BM (24-month PFS rates in patients with analytical active BM, LMC, and analytical stable BM were 32.7%, 25.1%, and 60.8%, respectively). Median OS was 27.0 months in patients with analytical active BM and NR in patients with LMC or analytical stable BM (24-month OS rates in patients with analytical active BM, LMC, and analytical stable BM were 52.0%, 61.6%, and 71.6%, respectively). The most common adverse event leading to discontinuation of T-DXd was interstitial lung disease (ILD; 23.1%); median ILD onset time among patients who discontinued T-DXd treatment due to ILD was 5.3 months. T-DXd has promising effectiveness in heavily pre-treated HER2+ metastatic breast cancer patients with BM and LMC. The incidence and median onset time of ILD were similar to those of Japanese subgroups in previous studies.
Identifiants
pubmed: 39133378
doi: 10.1007/s12282-024-01614-1
pii: 10.1007/s12282-024-01614-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23:894–904.
doi: 10.1093/neuonc/noaa285
pubmed: 33367836
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). npj Breast Cancer. 2023;9:82. https://doi.org/10.1038/s41523-023-00584-5 .
doi: 10.1038/s41523-023-00584-5
pubmed: 37821514
pmcid: 10567705
Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer. 2023;30:872–84.
doi: 10.1007/s12282-023-01505-x
pubmed: 37804479
Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1301–7.
doi: 10.2215/CJN.08630910
pubmed: 21493743
pmcid: 3109925
Nakayama T, Yoshinami T, Yasojima H, Kittaka N, Takahashi M, Ohtani S, et al. Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). BMC Cancer. 2021;21:795.
doi: 10.1186/s12885-021-08504-1
pubmed: 34238257
pmcid: 8268506
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, et al. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Breast Cancer. 2021;28:581–91.
doi: 10.1007/s12282-020-01192-y
pubmed: 33389616
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S et al. Poster Presentation: final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. San Antonio Breast Cancer Symposium 2023. Abstract PO2-04-05.
Batista MV, Pérez-García JM, Garrigós L, García-Sáenz JA, Cortez-Castedo P, Racca F et al. Spotlight Poster Presentation: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: results from Cohort 5 of the DEBBRAH study. San Antonio Breast Cancer Symposium 2023. Abstract PS11-05.
Hurvitz SA, Modi S, Li W, Park YH, Chung W, Kim S-B, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-breast (DB) -01, -02, and -03. Ann Oncol. 2023;34:S335–6.
doi: 10.1016/j.annonc.2023.09.554
Im SA, Xu B, Kim S-B, Chung W-P, Park YH, Kim M-H, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: results of the randomized phase 3 study DESTINY-Breast03. Ann Oncol. 2022;33:S464–5. Abstract PS2-1.
doi: 10.1016/j.annonc.2022.05.064
Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7:100554. https://doi.org/10.1016/j.esmoop.2022.100554 .
doi: 10.1016/j.esmoop.2022.100554
pubmed: 35963179
pmcid: 9434416
Riecke K, Müller V, Neunhöffer T, Park-Simon TW, Weide R, Polasik A, et al. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. ESMO Open. 2023;8:101213. https://doi.org/10.1016/j.annonc.2022.03.189 .
doi: 10.1016/j.annonc.2022.03.189
pubmed: 37075697
pmcid: 10265610
Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014;147:103–12.
doi: 10.1007/s10549-014-3090-8
pubmed: 25106661